GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Altamira Therapeutics Ltd (STU:2QA) » Definitions » Other Operating Expense

Altamira Therapeutics (STU:2QA) Other Operating Expense : €-0.35 Mil (TTM As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Altamira Therapeutics Other Operating Expense?

Altamira Therapeutics's Other Operating Expense for the six months ended in Dec. 2023 was €-0.24 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2023 was €-0.35 Mil.

Altamira Therapeutics's quarterly Other Operating Expense increased from Dec. 2022 (€-0.78 Mil) to Jun. 2023 (€-0.12 Mil) but then declined from Jun. 2023 (€-0.12 Mil) to Dec. 2023 (€-0.24 Mil).

Altamira Therapeutics's annual Other Operating Expense increased from Dec. 2021 (€-2.06 Mil) to Dec. 2022 (€-1.04 Mil) and increased from Dec. 2022 (€-1.04 Mil) to Dec. 2023 (€-0.13 Mil).


Altamira Therapeutics Other Operating Expense Historical Data

The historical data trend for Altamira Therapeutics's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Altamira Therapeutics Other Operating Expense Chart

Altamira Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.02 -0.16 -2.06 -1.04 -0.13

Altamira Therapeutics Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.06 -0.25 -0.78 -0.12 -0.24

Altamira Therapeutics Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-0.35 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Altamira Therapeutics Other Operating Expense Related Terms

Thank you for viewing the detailed overview of Altamira Therapeutics's Other Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Altamira Therapeutics (STU:2QA) Business Description

Traded in Other Exchanges
Address
2 Church Street, Clarendon House, Hamilton, BMU, HM11
Altamira Therapeutics Ltd is dedicated to developing therapeutics that address unmet medical needs. It is active in RNA therapeutics, allergy and viral infections, and inner ear disorders. Its product Bentrio is a drug-free nasal spray for personal protection against airborne viruses and allergens.

Altamira Therapeutics (STU:2QA) Headlines

No Headlines